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Abstract
Study Design: Review.
Objectives: The objectives of this review are to (a) summarize the role of clinical practice guidelines (CPGs), (b) outline the
methodology involved in formulating CPGs, (c) provide an illustration of these principles using a CPG developed for degenerative
cervical myelopathy, and (d) highlight the importance of knowledge translation.
Methods: A review of the literature was conducted to summarize current standards in CPG development and
implementation.
Results: CPGs are systematically developed statements intended to affect decisions made by health care providers, policy
makers, and patients. The main objectives of CPGs are to synthesize and translate evidence into recommendations, optimize
patient outcomes, standardize care, and facilitate shared decision making among physicians, patients, and their caregivers. The
main steps involved in the development of CPGs include defining the clinical problem, assembling a multidisciplinary guideline
development group and systematic review team, conducting a systematic review of the literature, translating the evidence to
recommendations, critically appraising the CPG and updating the document when new studies arise. The final step in developing a
CPG is to implement it into clinical practice; this step requires an assessment of the barriers to implementation and the for-
mulation of effective dissemination strategies.
Conclusion: CPGs are an important component in the teaching and practice of medicine and are available for a wide spectrum of
diseases. CPGs, however, can only be used to influence clinical practice if the recommendations are informed by a systematic
review of the literature and developed using rigorous methodology. The opportunity to transform clinical management of spinal
conditions is an attractive outcome of the application of high-quality CPGs.
Keywords
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Introduction
Clinical practice guidelines (CPGs) are systematically devel-
oped statements intended to affect decisions made by health
care providers, policy makers, and patients.1 They are based on
a rigorous review of the best available evidence and provide
recommendations on how to optimize patient management.2
Today, CPGs are an important component in the teaching and
practice of medicine and are available for a wide spectrum of
diseases.3 The main objectives of CPGs are to
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 Synthesize and translate the highest quality of evidence
into practice recommendations
 Optimize treatment outcomes and reduce the use of any
harmful or unnecessary interventions
 Establish standards of care and reduce inappropriate
practice variations
 Facilitate shared decision making among physicians,
patients and their caregivers
 Inform policy makers in their decisions about the allo-
cation of health care resources.
In contrast, CPGs are not intended to replace clinical judg-
ment or experience, be the sole source for management deci-
sions, influence reimbursement policies, or be used for
performance measures, legal precedents, or comprehensive
management.2,4,5 Quality health care requires the combination
of evidence, clinical expertise, and patient preferences.
Limitations in Previous Guidelines
There have been significant changes to the guideline devel-
opment process over the past 30 years.6 Traditionally, CPGs
consisted of consensus-based statements and recommenda-
tions generated by expert physicians. As evidence-based med-
icine has taken center stage, approaches for developing
guidelines have become more rigorous, requiring consider-
ation of past and present research. There can be, however,
substantial limitations in the evidence base that can ultimately
result in guidelines that are based largely on expert opinion.6-10
Such limitations include (a) a paucity of high-quality studies on
the efficacy and effectiveness of various medical interventions,
surgical treatments, drugs, and devices; (b) a lack of evidence on
rarer conditions or subpopulations such as those with lower
socioeconomic status; and (c) an inability to conduct randomized
controlled trials due to ethical considerations. Furthermore, even
if the results of studies are internally valid (ie, have limited
biases related to study design, conduct, and analysis), they may
not be generalizable or applicable to other populations (ie, not
externally valid), or they may not be feasible to implement due
to cost considerations.
Specific issues include (a) formation of a guideline devel-
opment group (GDG) without attention to intellectual or
financial conflicts of interest, (b) a lack of transparency in
the derivation of recommendations, (c) poor coordination
between the systematic review team and the GDG, (d) inabil-
ity to control for bias among key stakeholders, and (e) failure
to establish a well-balanced multidisciplinary GDG (6). As a
result of limitations in the body of evidence along with defi-
ciencies in the guideline development process, there are cur-
rently a number of conflicting recommendations for various
conditions, and a lack of clarity as to which CPG should be
used in practice.6
To address such shortcomings, the Institute of Medicine
updated their definition of CPGs to “statements that include
recommendations intended to optimize patient care that are
informed by a systematic review of the evidence and an
assessment of the benefits and harms of alternative care
options.”6 Furthermore, in the book Clinical Practice Guide-
lines We Can Trust, the Institute of Medicine outlines the min-
imal standards required for CPGs to be trustworthy.6
Specifically,
 Recommendations and suggestions must be informed by
a rigorous systematic review of the existing evidence
 CPGs must be developed by a knowledgeable multidis-
ciplinary group that includes physicians, patients, and
policy makers
 The process to develop CPGs must be transparent and
minimize biases, conflicts of interest, and other
distortions
 Recommendations must consider alternative treatment
options as well as health outcomes
 Each statement must be accompanied by a rating of the
quality of evidence and the strength of the
recommendation
 CPGs must be updated regularly and as new evidence
arises.
Along with these standards, the Guidelines International
Network also recommends that the CPG should specify its
objective and scope, be reviewed by external stakeholders
before publication and disclose any financial support received
for the development of either the systematic review or the
recommendations.11
CPGs should also outline reasonable implementation plans,
be flexible and adaptable to different settings and consider
local resources and feasibility.12 Finally, CPGs must be devel-
oped in such a way that they can be easily accessed and under-
stood by patients. Since the Institute of Medicine updated their
definitions of CPGs, there was a significant reduction in the
number of guidelines published in the National Guideline
Clearinghouse from 2619 in 2014 to 1440 in 2018.13 Previously
published CPGs that were not informed by a systematic review
of the literature were removed from the Clearinghouse.
Funding is another important consideration as there are sig-
nificant costs associated with the development of a CPG. Exter-
nally funded CPGs must explicitly state that the views and
interests of the funding body have not influenced the final
recommendations.4 Furthermore, appropriate management of
conflicts of interest is critical to ensure the CPG has complete
editorial independence from the funding source.
Overview of Guideline Methodology
Figure 1 provides an overview of the three critical steps
involved in the development of a CPG.
Define the Clinical Problem
The first step in creating a CPG is to identify critical knowledge
gaps and define the clinical problem, the scope and the target
audience. Selected topics should be both “high-priority” and
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feasible.14 The development of a CPG is considered “high-
priority” if there is
 Significant disease burden and cost of management
 Controversy or uncertainty around the topic and sup-
porting evidence
 New evidence arising that may impact current
recommendations
 Potential to improve health outcomes and quality of life,
reduce mortality and morbidity, and affect decision
making
 Public or provider interest
 Potential to reduce variations in care and cost.
Furthermore, proposed topics must have clear definitions of
the disease or the procedure of interest and there must be an
adequate evidence base to inform the recommendations.
The need for a CPG can also be evaluated by surveying key
stakeholder groups. For example, Nater et al15 conducted a
survey of the AOSpine International community to assess
whether members would benefit from a CPG outlining how
to manage perioperative neurologic deficit during spine sur-
gery. The survey also aimed to gauge the likelihood that sur-
geons would use this guideline in their clinical practice.
Information from surveys can be used to prioritize topics for
CPGs, evaluate current practice standards, and initiate the pro-
cess of knowledge translation.
Establish a Guideline Development
Group and Leadership
A GDG should be multidisciplinary and consist of 10 to 20
members.16 If multiple specialties are represented in the GDG,
Figure 1. An overview of the methodology involved in developing clinical practice guidelines.
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there is an increased likelihood that all contributory scientific
evidence will be identified and analyzed, and that any practical
problems in guideline application will be addressed.6 Members
of the group should include
 Specialists on the topic
 Nonspecialists who may either implement or be affected
by the CPG
 Physical therapists, allied health and nursing
professionals
 Patient advocates, public representatives, and caregivers
 Epidemiologists, statisticians, and experts in decision
analysis, informatics, and clinical or social psychology.
All participants are required to complete a disclosure form
outlining any financial, personal, or intellectual conflicts of
interest.5
The GDG should have a group leader who is qualified and
experienced in facilitating discussion among healthcare profes-
sionals and consumer representatives. The leader is responsible
for appointing a vice-chair, ensuring that key stakeholders are
adequately represented in the GDG and managing conflicts of
interest. The leader also “needs to allow sufficient time for all
members to express their views without feeling intimidated or
threatened and should check that all members in the group
agree to endorse any recommendation.”6 This individual must
remain neutral, encourage positive group processes and discou-
rage minority influence, group polarization, and “groupthink”
(ie, when members’ desire for unanimity override objective
appraisal of the evidence).17,18
Patients and their caregivers reflect the group that will be
most deeply affected by a CPG.6 They will undoubtedly bring
perspectives to discussions that differ from those of clinicians
and ensure that recommendations are presented in a way that is
understandable and accessible to patients.6 One of the chal-
lenges is that patients may lack the relevant training and sci-
entific literacy required to follow and meaningfully contribute
to discussions.6 Moreover, a consumer representative or a
patient suffering from the disease of interest may have personal
experiences that could interfere with their ability to accurately
evaluate the evidence and recommendations.6
Assemble a Multidisciplinary Systematic Review Team
Similar to the GDG, the systematic review team should be
multidisciplinary and include methodology experts. There can
be complete isolation, limited interaction or complete interac-
tion between the GDG and the systematic review team. The
Institute of Medicine highlights the advantages and disadvan-
tages of the varying levels of interaction.6
Conduct a Systematic Review of the Literature
Systematic reviews are required to summarize and synthesize
the evidence that will ultimately inform the CPG. The PRISMA
statement (Preferred Reporting Items for Systematic reviews
and Meta-Analyses) outlines the minimum set of items
required for a systematic review or meta-analysis.19 Figure 2
highlights the methodology involved in conducting a systema-
tic review:
1. Protocol and Registration: It is recommended that the
protocol for each systematic review is registered with
PROPSERO, an international prospective register of
systematic reviews.20
2. Clinical Question: A clinical question should be
developed in the format “should A (versus B) be used
to treat/manage patients with C?”
3. Eligibility Criteria: Detailed inclusion and exclusion
criteria should be defined before conducting a data-
base search. The use of a PICO (population, interven-
tion, comparison, outcome) or PPO (population,
prognostic factor, outcome) table is recommended.21
Furthermore, any limitations on language, years of
publication, and study design should be specified a
priori.
Figure 2. An overview of the methodology required for a systematic
review.
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4. Information Sources: EMBASE, MEDLINE, the
Cochrane Central Register of Controlled Trials, and
other relevant databases should be searched.22
5. Search: A detailed search strategy should be devel-
oped, preferably with the help of a librarian. Searches
should be highly sensitive and use both free-text and
subject headings.
6. Study Selection: Two independent reviewers should
screen all abstracts (and full texts, where necessary)
to determine which studies satisfy the inclusion and
exclusion criteria.
7. Data extraction: Two independent reviewers should
also extract the relevant data from each study using
data collection forms or other unified methodology.
Furthermore, in cases where invaluable information
is missing from the study, steps should be taken to
acquire this information (eg, contacting the primary
investigator). Finally, any assumptions or simplifica-
tions applied during data extraction should be noted.
8. Assess Risk of Bias of Individual Studies: Numerous
tools, such as the Newcastle Ottawa Scale and Crit-
ical Appraisal Skills Programme tool, are available to
evaluate the quality of primary studies.23,24 The main
types of bias that should be assessed are selection,
performance, detection, information, reporting and
attrition bias.
9. Summarize Findings
10. Evaluate Risk of Bias Across Studies: The strength of
the overall body of evidence should be determined.
Methods proposed by the GRADE (Grading of Rec-
ommendation, Assessment, Development, and Eva-
luation) Working Group have been increasingly used
to evaluate risk of bias across studies and to determine
how confident one can be about the estimate of
effect.25,26
Several organizations that advocate evidence-based medi-
cine have endorsed the GRADE process, including the World
Health Organization, the BMJ Clinical Evidence and the
Agency for Health Research and Quality (AHRQ).27
The initial rating of the quality of evidence is based on
whether the studies are randomized controlled trials (baseline
level ¼ HIGH) or observational studies (baseline level ¼
LOW).26 The quality of evidence may then be upgraded or
downgraded based on a number of factors. Criteria for down-
grading the quality by 1 or 2 levels include limitations in the
study design or execution, inconsistency of results, indirectness
of evidence, imprecision, and publication bias.28-32 Alterna-
tively, criteria for upgrading the quality by 1 or 2 levels include
a large magnitude of effect, if plausible confounding would
reduce the demonstrated effect or increase the effect if no effect
was observed, or if there was a dose-response gradient.33 Table
1 summarizes how to determine whether the quality of evi-
dence should be upgraded or downgraded.
Following this process, the quality of evidence can be con-
sidered high, moderate, low, or very low (Table 2).26
Development of Clinical Practice Guidelines
The development of CPGs requires the formation of recom-
mendations using evidence summarized in a systematic review.
The initial step in any guideline project is to construct a pro-
tocol that includes the general focus, purpose, and rationale of
the CPG, relevant definitions, aspects of care covered by the
guideline, users, and implementation strategies. The next steps
consist of examining and critiquing the evidence, formulating
evidence based-recommendations, evaluating the overall cer-
tainty of the evidence, and defining the strength of recom-
mendations. Several tools can be used to guide the
development process, including the Conference on Guide-
line Standardization (COGS) checklist for reporting CPGs,
the AGREE (Appraisal of Guidelines for Research and
Evaluation) tool, the ADAPTE framework, the GRADE
guideline development tool (GDT), and the evidence-to-
recommendation framework.10,34-38
The GRADE “evidence-to-recommendation” framework is
increasingly used to guide the development process. This tool
consists of several questions aimed to assess the benefits and
harms, resource use, the impact on health inequities, the accept-
ability, and the feasibility of various treatment options (Table
3).39 This framework ensures that (a) all important factors that
influence a recommendation are considered, (b) judgments
about each factor are informed by the best available evidence,
(c) discussions are structured, (d) reasons for disagreement
among members of the GDG are identified, and (e) the ratio-
nale for each recommendation is transparent to the target
audience.
The final step in the process is to balance the consequences
and determine the strength of each recommendation (Table 3).
The 4 factors that influence the strength of the recommendation
are the balance between desirable and undesirable outcomes,
the confidence in the magnitude of the estimate of effect (as
gauged by the quality of the evidence), the confidence in values
and preferences of key stakeholders and resource use.40,41 The
wording of the recommendation signifies whether it is “strong”
or “weak.” Specifically, the word “recommend” denotes a
stronger recommendation, whereas the word “suggest” indi-
cates a weaker recommendation.5
The strength of the recommendation has different implica-
tions for patients, clinicians, and policy makers. A strong rec-
ommendation means that (a) most patients would want to
receive the recommended course of action and only a small
proportion would not, (b) most patients should receive the
recommended course of action, and (c) the recommendation
can be adapted as policy in most situations and be used as a
performance indicator.36,40 Furthermore, formal decision aids
are unlikely to be needed to assist patients in making a decision
consistent with their values and preferences.40 A weak recom-
mendation means that (a) the majority of individuals would
want the suggested course of action but many would not, (b)
clinicians must recognize that different choices will be appro-
priate for different patients and should help a patient arrive at a
decision consistent with his or her values or preferences, and
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(c) policy making will require substantial debates and involve-
ment of many stakeholders.36,40
Guideline Appraisal Tools
It is often the case that multiple CPGs are published with con-
flicting recommendations on the same topic. These differences
may arise due to variations in practice standards across coun-
tries or due to discrepancies in opinions related to the antici-
pated harms, benefits, cost-effectiveness, feasibility, and
acceptability of each recommendation.42 In contrast, contradic-
tory CPGs may be a result of conflicts of interest, failure of the
GDG to critically appraise the evidence or inadequate represen-
tation of important stakeholder groups.42 Clinicians must be able
to identify CPGs that have been rigorously developed and are
based on a systematic assessment of the evidence.
Table 2. Interpretation of Quality of Evidence Ratings.a
Grade Definition
High High confidence in the effect estimate.
The true effect lies close to that of the estimate of effect.
Moderate Moderate confidence in the effect estimate.
The true effect is likely to be close to the estimate of
effect, but there is a possibility that it is substantially
different.
Low Limited confidence in the effect estimate.
The true effect may be substantially different from the
estimate of effect.
Very low Very little confidence in the effect estimate.
The true effect is likely to be substantially different from
the estimate of effect.
aDerived from the GRADE handbook.33
Table 1. Reasons for Upgrading or Downgrading the Quality of the Overall Body of Evidence.a
Factor Examples Consequence
Factors than can downgrade the quality of evidence
Limitations in study design or execution
(risk of bias)
 RCT: lack of allocation concealment, lack of blinding,
incomplete accounting of patients and outcome events,
selective outcome reporting
 Observational studies: failure to develop and apply
appropriate eligibility criteria, failure to control
confounding, flawed measurement of both exposure and
outcome, incomplete or inadequately short follow-up
Downgrade 1 or 2 levels
Inconsistency of results Unexplained heterogeneity of results across studies:
 Wide variance of point estimates across studies
 Minimal or no overlap of confidence intervals
 Statistical criteria (eg, tests of heterogeneity) have a low P
value
Downgrade 1 or 2 levels
Indirectness of evidenceb Sources of indirectness include
 Differences in population
 Differences in interventions
 Differences in outcome measures
 Indirect comparison
Downgrade 1 or 2 levels
Imprecision  Wide confidence intervals
 Optimal information size criterion not met
Downgrade 1 or 2 levels
Publication bias  Selective publication of “positive” results
 Selective rejection of manuscripts with “negative” results
Downgrade 1 or 2 levels
Factors that can upgrade the quality of evidence
Large magnitude of effectc Very large: RR >5 or <0.2
Large: RR >2 or <0.5
Upgrade 1 or 2 levels
All plausible confounding would reduce the
demonstrated effect or increase the effect if
no effect was observed
N/A Upgrade 1 level
Dose-response gradient N/A Upgrade 1 level
Abbreviations: N/A, not applicable; RCT, randomized controlled trial; RR, relative risk.
aDerived from the GRADE handbook.33
bDirect evidence directly compares the interventions of interest delivered to the populations of interest and measures the outcomes important to the patients.
cOnly applied to relative risks or hazard ratios. May not be applicable to odds ratios (ORs); GRADE suggests converting OR to RR and then assessing the
magnitude of effect.
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The Appraisal of Guidelines for Research and Evaluation
(AGREE) II is an instrument designed to assess the quality of
and provide a framework for the development and reporting of
CPGs.35 The AGREE II can be used by (a) health care provi-
ders and policy makers to evaluate which CPG should be used
in practice or to inform policy decisions, (b) guideline devel-
opers to ensure rigorous methodology and guideline validity,
and (c) educators to improve critical appraisal skills among
health care professionals.
The AGREE II consists of 23 items rated on a 7-point scale
(1 ¼ strongly disagree, 7 ¼ strongly agree) in the following
domains: scope and purpose, stakeholder involvement, rigor of
development, clarity of presentation, applicability, and editor-
ial independence.43 There are also 2 global rating items that
include the rating of the overall quality of the guideline and
whether the guideline should be recommended for use in clin-
ical practice. Table 4 summarizes the key questions included in
AGREE II.
The CPG should be externally appraised by a multidisciplin-
ary group of clinicians, a patient advocate, and other relevant
stakeholders.
Update Planning
The Guidelines International Network and the Institute of Med-
icine have outlined important standards for updating CPGs.6,11
They suggest that the literature should be monitored regularly
to identify the emergence of new evidence and to evaluate the
ongoing validity of the CPG. Specifically, an update is neces-
sary if there are changes in the evidence related to benefits and
harms, outcomes that would be considered critical for decision
making, ranking of current outcomes and available interven-
tions and resources.44 Developers should specify a detailed
plan for updating a CPG.
An Illustrative Example
In 2017, 6 CPGs were developed to outline how to best manage
patients with degenerative cervical myelopathy (DCM) and
spinal cord injury (SCI).45-50 Table 5 summarizes the steps
involved in guideline development by using the DCM guide-
line as an example.
Knowledge Translation
Knowledge translation is defined as “the exchange, synthesis
and application of knowledge to accelerate the benefits of
research through improved health, more effective services and
products, and a strengthened health care system.”51 The first
step in any form of knowledge translation is to identify critical
knowledge gaps and define the clinical problem.
Figure 3 summarizes the knowledge-to-action framework
proposed by Graham et al.52 This framework consists of 2
distinct but related components: knowledge creation, repre-
sented by the funnel in the center of the figure, and the sur-
rounding action cycle. These 2 components are closely related
and can influence each other.
Knowledge creation includes “knowledge inquiry” (ie, the
multitude of primary studies available to date), “knowledge
Table 3. The Evidence-to-Recommendation Framework.a
Question Response Options
Benefits and harms
What is the overall certainty of
the evidence?
No included studies, very low,
low, moderate, high
Is there important uncertainty
about how much people
value the main outcomes?
Important uncertainty or variability,
possibly important uncertainty
or variability, probably no
important uncertainty or
variability, no important
uncertainty or variability, no
known undesirable
Are the desirable anticipated
effects large?
No, probably no, uncertain,
probably yes, yes, varies
Are the undesirable anticipated
effects small?
No, probably no, uncertain,
probably yes, yes, varies
Are the desirable effects large
relative to the undesirable
effects?
No, probably no, uncertain,
probably yes, yes, varies
Resource use
Are the resources required
small?
No, probably no, uncertain,
probably yes, yes, varies
Is the incremental cost small
relative to the net benefit?
No, probably no, uncertain,
probably yes, yes, varies
Equity
What would be the impact on
health inequities?
Increased, probably increased,
uncertain, probably reduced,
reduced, varies
Acceptability
Is the option acceptable to key
stakeholders?
No, probably no, uncertain,
probably yes, yes, varies
Feasibility
Is the option feasible to
implement?
No, probably no, uncertain,
probably yes, yes, varies
Balance of the consequences
What is the balance between
undesirable and desirable
consequences?
Undesirable consequences clearly
outweigh desirable
consequences, undesirable
consequences probably
outweigh desirable
consequences in most settings,
the balance between desirable
and undesirable consequences
is closely balanced or uncertain,
desirable consequences
probably outweigh undesirable
consequences in most settings,
desirable consequences clearly
outweigh undesirable
consequences in most settings
Type of recommendation
What is the strength and
direction of the
recommendation?
We recommend against offering
this option we suggest not
offering this option, we suggest
offering this option, we
recommend offering this option
aDerived from the Decide Collaboration.39
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synthesis” (ie, the aggregation of existing knowledge through
rigorous systematic reviews or meta-analyses), and
“knowledge tools” (ie, clinical practice guidelines, decision
aids, and care pathways).52 The surrounding action cycle out-
lines the steps required to effectively translate knowledge cre-
ation into practice and sustain knowledge use. These include
assessing barriers to knowledge use, devising effective disse-
mination and implementation strategies, monitoring knowl-
edge use, and evaluating outcomes.
Assessing Barriers to Implementation
The development of a CPG does not necessarily equate to
changes in clinical practice. In fact, CPGs are often not applied.
As a result, it is estimated that 30% to 40% of patients receive
treatment that is not based on scientific evidence and 20% to
25% of patients are managed with either useless or potentially
harmful interventions.53
Barriers to the implementation and adherence of CPGs can
be categorized into personal, guideline-related, and external
factors.54-56 Personal factors include those related to physi-
cians’ knowledge (ie, lack of awareness or lack of familiarity
with the CPG and its recommendations), physicians’ attitude
(ie, lack of agreement, self-efficacy, skills, motivation, out-
come expectancy, and learning culture), and patients’ desires
(ie, inability to reconcile patient preferences with the use of
knowledge).54-56 Guideline-related factors are those that
impact the validity, accessibility, and applicability of the rec-
ommendations (eg, lack of evidence, complexity, poor layout,
inaccessibility, lack of applicability, and lack of clear interven-
tion goals).55 Finally, external factors impeding the implemen-
tation of CPGs include organizational constraints, lack of
resources and time, and lack of collaboration.55
Develop Effective Dissemination and
Implementation Strategies
Effective dissemination and implementation strategies must
address the aforementioned barriers.55 Strategies include
 Address physicians’ awareness and familiarity by
increasing the dissemination of the guideline, using
mass media or educational posters in examination
rooms, and organizing continuing medical education
activities that focus on specific recommendations.
 Address issues with physicians’ attitudes by using opin-
ion leaders, obtaining endorsement from special societ-
ies, organizing educational meetings, interactive
learning and outreach visits, and providing feedback
on individual performance.
 Address guideline related factors by employing methods
of evidence-based medicine, critically appraising the
recommendations, regularly updating the content, and
using tablets, smartphones, and mobiles for the provi-
sion of guidelines.
Table 4. The Appraisal of Guidelines for Research and Evaluation
(AGREE) II.a
Domain Key Items
1. Scope and
purpose
 The overall objective(s) of the guideline is
(are) specifically described.
 The health question(s) covered by the
guideline is (are) specifically described.
 The population to whom the guideline is
meant to apply is specifically described.
2. Stakeholder
involvement
 The guideline development group includes
individuals from all relevant professional
groups.
 The views and preferences of the target
population have been sought.
 The target users of the guideline are clearly
defined.
3. Rigor of
development
 Systematic methods were used to search
for evidence.
 The criteria for selecting the evidence are
clearly described.
 The strengths and limitations of the body of
evidence are clearly described.
 The methods for formulating the
recommendations are clearly described.
 The health benefits, side effects, and risks
have been considered in formulating the
recommendations.
 There is an explicit link between the
recommendations and the supporting
evidence.
 The guideline has been externally reviewed
by experts prior to its publication.
 A procedure for updating the guideline is
provided.
4. Clarity of
presentation
 The recommendations are specific and
unambiguous.
 The different options for management of the
conditionor health issue are clearly presented.
 Key recommendations are easily
identifiable.
5. Applicability  The guideline describes facilitators and
barriers to its application.
 The guideline provides advice and/or tools
on how the recommendations can be put
into practice.
 The potential resource implications of
applying the recommendations have been
considered.
 The guideline presents monitoring and/or
auditing criteria.
6. Editorial
independence
 The views of the funding body have
not influenced the content of the
guideline.
 Competing interests of guideline
development group members have been
recorded and addressed.
aDerived from the AGREE II User Manual.42
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 Address external barriers by standardizing processes and
procedures, improving collaboration among health care
professionals, and providing adequate time for the doc-
umentation and utilization of the guidelines.
Monitoring Knowledge Use and Evaluating Outcomes
Other important components of the knowledge-to-action
framework include monitoring knowledge use and evaluating
outcomes. There are three different types of knowledge use:
conceptual (ie, changes in level of knowledge, understanding
or attitudes), instrumental (ie, changes in behavior or practice),
and strategic (ie, manipulation of knowledge to attain specific
power or profit goals).52 These can be evaluated by (a) asses-
sing patient attitudes and resource use through surveys and (b)
determining the use of care pathways through secondary
analysis.
The subsequent phase in the framework is to evaluate the
impact of knowledge use on the patient, the physician and the
organization. Specifically, the impact on the patient can be
measured by improved health status, quality of life and satisfac-
tion, as well as reduced length of hospital stay. The impact on
physicians can be assessed using questionnaires and interviews
that focus on improved satisfaction with practice and increased
time dedicated to new practice. Finally, the impact on organiza-
tions can be evaluated through analysis of wait times, length of
stay, and costs using administrative or clinical databases.
Adapting Guidelines to Different Settings
CPGs developed in one country can be adapted and used in
another country. The benefits of transferring guidelines across
institutions include avoiding duplication of effort, reducing
unnecessary use of resources, and enhancing efficiency.57 The
ADAPTE collaboration group was developed to define a pro-
cess for adapting existing CPGs to different settings.37 Impor-
tant tenets of this process include
 Acknowledge evidence-based principles in guidelines
 Use reliable methodology that promotes the quality of
adapted guideline
Table 5. An Illustrative Example.
Step Action
Define the clinical problem What is the best management strategy for patients with mild, moderate and severe DCM and
nonmyelopathic patients with evidence of cord compression?
Establish a guideline development group
and leadership
The GDG group was multidisciplinary and consisted of neurosurgeons, orthopedic surgeons,
neurologists, rheumatologists, rehabilitation specialists, epidemiologists, a physiotherapist, a nurse,
and a patient advocate.
Assemble a multidisciplinary systematic
review team
The systematic review team was also multidisciplinary and contained some, but not all, members from
the GDG.
Conduct a systematic review of the
literature
Systematic reviews were conducted to summarize the natural history, the comparative efficacy of
operative versus non-operative management, the expected functional, disability and pain outcomes
following surgery and nonoperative treatment and the management of nonmyelopathic patients
with cervical spinal cord compression, canal stenosis, and/or OPLL.
Development of clinical practice
guidelines
The CPG addressed the following questions:
 Should operative management be used to treat patients with severe DCM?
 Should operative management be used to treat patients with moderate DCM?
 Should nonoperative management be used to treat patients with mild DCM?
 Should operative management be used to treat patients with mild DCM?
 Should operative management be used to treat nonmyelopathic patients with imaging evidence of
cord compression without signs or symptoms of radiculopathy?
 Should operative management be used to treat nonmyelopathic patients with imaging evidence of
cord compression and clinically/electrophysiologically diagnosed radiculopathy?
Recommendations were developed based on the systematic reviews, benefits and harms, resource
use, impact on health inequities, acceptability and feasibility.
The GRADE evidence-to-recommendation framework was used to facilitate discussions and
document the process.
Finally, the GDG weighed the undesirable and desirable consequences, formulated the
recommendations and agreed on the strength of each recommendation.
Guideline appraisal The AGREE II tool was used to appraise the CPG. The CPG was also evaluated externally by a
multidisciplinary group of clinicians, a patient advocate, AOSpine North America, AOSpine
International, and the Cervical Spine Research Society.
Update planning The CPG will be reviewed by the primary sponsor every 3 to 5 years following publication.
Abbreviations: AFREE II, Appraisal of Guidelines for Research and Evaluation II; CPG, clinical practice guidelines; DCM, degenerative cervical myelopathy; GDG,
guideline development group; GRADE, Grading of Recommendation, Assessment, Development, and Evaluation; OPLL, ossification of the posterior longitudinal
ligament.
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 Encourage participation of key stakeholders to ensure
acceptance of the guideline and to promote its use
 Evaluate the feasibility of implementing the guideline
and assess its relevance in local practice and policy
 Report the recommendations with transparency
 Provide a flexible format of the guideline to accommo-
date specific needs and circumstances.
Based on these principles, a comprehensive framework was
developed that consisted of 3 main phases with 24 steps: (a)
set-up (prepare for adapt framework), (b) adaptation (search
and screen guidelines, assess guidelines, decide and select, and
draft guideline report), and (c) finalization (external review,
plan for future review and update, produce final guideline).37
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